国泰海通证券股份有限公司 关于青岛海泰新光科技股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 青岛海泰新光科技股份有限公司（以下简称"海泰新光"或"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作（2025 年 5 月修订）》和《上海证券交易所科创板股票上 市规则》等有关规定，对海泰新光使用部分闲置募集资金暂时补充流动资金的事 项进行了核查，核查情况如下： 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2020 年 9 月 29 日审核同意，并经 中国证券监督管理委员会 2021 年 1 月 12 日《关于同意青岛海泰新光科技股份有 限公司首次公开发行股票注册的批复》（证监许可[2021]90 号）核准，同意公司 公开发行人民币普通股 21,780,000 股，发行价格为人民币 35.76 元/股。募集资 金总额为人民币 778,852,800.00 元，扣减承销费（不含增值税）人 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-039 青岛海泰新光科技股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●青岛海泰新光科技股份有限公司（以下简称"公司"）于 2025 年 8 月 1 日召开第四届董事会第五次会议及第四届监事会第五次会议，审议通过了《关于 使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用闲置募集资金 不超过人民币 15,000 万元（含本数）暂时补充流动资金，并仅用于公司的业务 拓展、日常经营等与主营业务相关的生产经营活动。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2020 年 9 月 29 日审核同意，并经 中国证券监督管理委员会 2021 年 1 月 12 日《关于同意青岛海泰新光科技股份有 限公司首次公开发行股票注册的批复》（证监许可[2021]90 号）核准，同意本 公司公开发行人民币普通股 21,780,000 股，发行价格为人民币 35.76 元/股。募 集 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-040 青岛海泰新光科技股份有限公司 第四届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 青岛海泰新光科技股份有限公司（以下简称"公司"）第四届监事会第五次 会议于 2025 年 8 月 1 日 11:00 在公司会议室以现场与通讯表决相结合的方式召 开，会议通知于 2025 年 7 月 25 日以邮件方式送达。公司监事 3 人，实际参会监 事 3 人。会议由公司监事会主席郑今兰女士主持，会议的召集和召开程序符合《中 华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： （一）审议通过《关于使用部分闲置募集资金暂时补充流动资金的公告》； 公司本次拟使用额度不超过总金额人民币 15,000 万元（含本数）的部分闲 置募集资金暂时补充流动资金，不存在变相改变募集资金使用投向的情形，不影 响募集资金投资项目的正常进行。公司本次拟使 ...

格隆汇8月1日丨海泰新光(688677.SH)公布，截至2025年7月31日，青岛海泰新光科技股份有限公司通过 上海证券交易所交易系统以集中竞价交易方式回购公司股份138.7万股，占公司总股本的比例为 1.15770%，回购成交的最高价40.92元/股，最低价为28.53元/股，支付的资金总额为人民币4998.22万元 （不含印花税、交易佣金等交易费用）。 ...

格隆汇8月1日丨海泰新光(688677.SH)公布，公司于2025年8月1日召开第四届董事会第五次会议及第四 届监事会第五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司 使用闲置募集资金不超过人民币15,000万元（含本数）暂时补充流动资金，并仅用于公司的业务拓展、 日常经营等与主营业务相关的生产经营活动。 ...

Core Viewpoint - Haitai Newlight is leading significant innovations in the endoscope industry with its first LED light source, first fluorescence endoscope, and first optical de-fogging system, positioning itself as a key player in the medical device market [2][3]. Company Background - Haitai Newlight transitioned from micro-projection display technology to the medical endoscope sector, leveraging its deep understanding of optical technology [3]. - The company established a strong partnership with global leaders in the endoscope market, which accelerated its innovation momentum [4]. Technological Innovations - The introduction of LED light sources has significantly improved brightness by over 20% compared to traditional xenon lamps, marking the entry of endoscopes into the LED era [3]. - Haitai Newlight developed the world's first coaxial fluorescence endoscope, enhancing surgical accuracy by allowing visualization of structures beneath the skin [5]. - The company launched the first optical de-fogging endoscope system in 2023, utilizing specific light to achieve thermal balance and eliminate fog [5]. Market Strategy - Haitai Newlight aims to build its own brand in the domestic market, having initiated brand development and marketing strategies since 2018 [8]. - The company has established a marketing team and centers across key provinces to facilitate clinical trials and product testing in hospitals [8][9]. - The domestic market share of international giants has decreased from 70%-80% to around 50% due to the rise of local brands [8]. Future Outlook - The company plans to expand its product line and integrate AI and robotic technologies to enhance its offerings [6][11]. - Haitai Newlight's development strategy includes deepening its core product capabilities while broadening its product line to meet diverse medical needs [11].

Core Insights - The article highlights the innovative advancements made by Haitai New Light in the endoscope industry, including the introduction of the first LED light source, the first fluorescence endoscope, and the first optical de-fogging system, positioning the company as a leader in the global endoscope market [1][2][4] Company Background - Haitai New Light transitioned from a micro-projection display business to the medical endoscope sector in 2008, leveraging its deep understanding of optical technology [2][3] - The company initially faced challenges with its micro-projection technology but successfully pivoted to endoscopes by developing a LED light source that outperformed existing solutions [2][4] Technological Innovations - The introduction of LED technology in endoscopes marked a significant shift, improving brightness by over 20% compared to traditional xenon lamps [2] - Haitai New Light developed the world's first fluorescence endoscope with a focus on achieving focal functionality for 10mm and 5mm laparoscopes, which gained popularity in North America [4] - In 2023, the company launched the first optical de-fogging endoscope system, utilizing specific light to achieve thermal balance and eliminate fog, a problem that had plagued traditional systems [5] Market Position and Strategy - Haitai New Light aims to establish its own brand in the domestic market, moving beyond being an ODM for international companies, and has initiated a comprehensive marketing strategy to support this goal [6][7] - The company has built a competitive edge by being the only domestic manufacturer with capabilities in light source, lens, and imaging system design and production [6] Industry Trends - The Chinese endoscope market is projected to grow from approximately 24.8 billion yuan in 2021 to 60 billion yuan by 2030, with a compound annual growth rate of 8.1% from 2025 to 2030 [7] - The endoscope sector is recognized as a rapidly growing segment within the global medical device market, with applications across various medical fields [7][8] Future Outlook - Haitai New Light has outlined a strategic plan termed "one vertical and two horizontals," focusing on deepening its core product offerings while expanding into related technologies such as AI and robotics [8] - The company anticipates significant growth in its self-branded products over the next few years, driven by an expanded marketing team and sales channels [7][8]

最新一期业绩显示，2025年一季报，公司实现营业收入1.47亿元，同比24.86%；净利润4668.87万元， 同比21.45%，销售毛利率64.98%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海泰新光35.1537.303.7650.48亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.41亿11三鑫医疗 20.0220.033.2945.55亿12鱼跃医疗20.0519.662.71355.08亿 7月29日，海泰新光今日收盘42.11元 ...

青岛海泰新光科技股份有限公司（以下简称"公司"）于 2024 年 7 月 30 日召开第三届董事会第二十二次会议及第三届监事会第十七次会议，审议通过 了《关于使用部分闲置募集资金暂时补充流动资金的议案》。同意公司使用闲 置募集资金不超过人民币 12,000 万元（含本数）暂时补充流动资金，并仅用于 公司的业务拓展、日常经营等与主营业务相关的生产经营活动，使用期限自公 司董事会审议通过之日起不超过 12 个月。具体内容详见公司 2024 年 7 月 31 日 披露于上海证券交易所网站（www.sse.com.cn）的《青岛海泰新光科技股份有 限公司关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号： 2024-042）。根据上述决议，公司在规定期限内使用了 12,000 万元闲置募集资 金暂时补充流动资金，并对资金进行了合理的安排与使用，没有影响募集资金 投资项目建设进度的正常进行。 截至本公告日，公司已将上述暂时补充流动资金的 12,000 万元闲置募集资 金全部归还至募集资金专用账户，并将募集资金的归还情况通知了保荐机构和 保荐代表人。本次闲置募集资金暂时补充流动资金期限自董事会审议通过之日 起未超 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].